Bristol-Myers Squibb(US:BMY) Xin Lang Cai Jing·2025-12-29 23:23Core Viewpoint - The application for Azacitidine by Excella GmbH & Co. KG has been accepted by the National Medical Products Administration, indicating a significant step in the drug approval process in China [1] Group 1: Drug Application Details - The application for Azacitidine was accepted on December 30, 2025, with the acceptance number JTH2500208 [1] - The application type is for import registration, classified as a chemical drug [1] Group 2: Company Information - Excella GmbH & Co. KG is associated with Bristol-Myers Squibb Pharma EEIG and Bristol-Myers Squibb (China) Investment Co., Ltd. [1] - Bristol-Myers Squibb (China) Investment Co., Ltd. was established on November 9, 1998, and is a large-scale foreign-owned limited liability company with a registered capital of 10,500 million USD [1] - The company is located at 17th Floor, 1717 Nanjing West Road, Jing'an District, Shanghai, and has 921 insured employees [1]